In-vitro analysis of aspirin pellets: Enhance Bioavailability and Stability with SEM test

Aspirin (75 mg) prevents the formation of blood clotting after a heart attack or stroke. To create a new aspirin dosage form and enhance its bioavailability by preventing pre-systemic elimination. Five aspirin formulations of drugs were prepared and evaluated for LOD, edema index, and in vitro dissolution. The substance was mixed with sodium alginate in ratios of 1:3, 1:4, and 1:5, and the percentages of CaCl2 solution were determined using an ultraviolet spectrophotometer with a maximum wavelength of 265nm. The beads were extracted from the solution and desiccated in the air. 8 hours were spent conducting dissolution tests in a 900-ml phosphate buffer with a pH of 7.2 and a rotational speed of 50 rpm at 37 + 0.5 0 C. Weight loss was greater in F-1 with a drug-polymer ratio of 1:3 and an electrolyte concentration of 5%, causing edema. 8 hours of in-vitro dissolution experiments were conducted in a 900-ml phosphate buffer with a pH of 7.2 and a speed of 50 rpm in a dissolution tester at 37 + 0.5 0 C. The drug release, as measured by a UV spectrophotometer at 265 nm, increased with decreasing electrolyte solution concentration and decreased with increasing polymer concentration. The most important concept is that aspirin-cross-linked alginate beads were produced by adjusting the CaCl2 concentration and drug-polymer ratio in order to decrease drug release and increase medication release.